Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,142.40
(
0.53%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.65
(
2.39%
)
Bitcoin
74,637.78
(
-0.28%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 145237

Friday, 09/07/2012 10:27:26 AM

Friday, September 07, 2012 10:27:26 AM

Post# of 257253
JNJ resubmits Xarelto NDA in PCI sub-indication of ACS:

http://finance.yahoo.com/news/janssen-research-development-submits-complete-120000837.html

This NDA, which is separate from the rejected Xarelto NDA in ACS per se, was voluntarily withdrawn by JNJ in July 2012 (#msg-77346396). In today’s PR, JNJ confirms that the additional information in the resubmission for PCI is in response to questions raised by the FDA in the June CRL rejecting the NDA in ACS (#msg-76856261).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now